Department of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan University, Bhubaneshwar, Odisha, India.
Department of Pathology, IMS & SUM Hospital, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India.
J Egypt Natl Canc Inst. 2024 Jan 29;36(1):3. doi: 10.1186/s43046-024-00207-5.
Targeted therapies against programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC) have revolutionized the management in recent years. There is paucity of data on the significance of PD-L1 expression in NSCLC from India. We aimed to study the prevalence of PD-L1 expression and its relation with different clinico-pathological parameters in advanced NSCLC from a tertiary care center in Eastern India.
All consecutive patients with advanced NSCLC diagnosed from January 2020 to December 2021 were prospectively evaluated for PD-L1 expression in formalin fixed-paraffin embedded tumor tissue specimens using immunohistochemistry analysis. A PD-L1 expression of < 1%, 1-49%, and ≥ 50% were considered negative, low, and high expression positive respectively, and association with various parameters was performed.
Out of the 94 patients (mean age 59.6 ± 14 years and 63.8% males), PD-L1 positivity was seen in 42 (44.7%) patients, with low positivity (1-49%) in 29 patients and high positivity (≥ 50%) in 13 patients. Epidermal Growth Factor Receptor (EGFR) mutations were seen in 28 patients (29.8%). There were no significant differences in PD-L1 positivity with respect to gender, age, and molecular mutation status. PD-L1 positivity was significantly associated with tobacco use (p = 0.04), advanced tumor stage (p < 0.001), and higher nodal stage (p < 0.001). Median overall survival in the cohort was 17 months and it was not significantly different between the PD-L1 positive and negative groups.
Forty-five percent of advanced NSCLC patients in our cohort showed positive PD-L1 expression and it is associated with tobacco use and aggressive tumor characteristics.
针对程序性死亡配体-1（PD-L1）的靶向治疗在非小细胞肺癌（NSCLC）中的应用近年来取得了革命性的进展。然而，来自印度的 NSCLC 中 PD-L1 表达的意义的数据却很少。我们旨在研究来自印度东部一家三级护理中心的晚期 NSCLC 中 PD-L1 表达的流行率及其与不同临床病理参数的关系。
所有连续的 2020 年 1 月至 2021 年 12 月期间诊断为晚期 NSCLC 的患者均前瞻性评估了福尔马林固定石蜡包埋肿瘤组织标本中 PD-L1 的表达情况，使用免疫组织化学分析。将 PD-L1 表达<1%、1-49%和≥50%分别定义为阴性、低表达和高表达阳性，并对其与各种参数的相关性进行分析。
94 例患者（平均年龄 59.6±14 岁，63.8%为男性）中，42 例（44.7%）患者 PD-L1 阳性，其中 29 例为低表达（1-49%），13 例为高表达（≥50%）。28 例患者（29.8%）存在表皮生长因子受体（EGFR）突变。PD-L1 阳性与性别、年龄和分子突变状态无关。PD-L1 阳性与吸烟史（p=0.04）、肿瘤晚期（p<0.001）和更高的淋巴结分期（p<0.001）显著相关。该队列的中位总生存期为 17 个月，PD-L1 阳性和阴性组之间无显著差异。
我们队列中的 45%的晚期 NSCLC 患者 PD-L1 表达阳性，与吸烟史和侵袭性肿瘤特征相关。
Zotero 插件